Sarepta Therapeutics Stock
Price
Target price
€108.50
€108.50
-0.910%
-1.0
-0.910%
€130.00
12:37 / Tradegate
WKN: A1J1BH / Symbol: AVII / Name: Sarepta / Stock / Biotechnology & Medical Research / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Sarepta Therapeutics Stock
Sarepta Therapeutics shows a slight decrease today, losing -€1.000 (-0.910%) compared to yesterday.
The community is currently still undecided about Sarepta Therapeutics with 1 Buy predictions and 0 Sell predictions.
With a target price of 130 € there is a slightly positive potential of 19.82% for Sarepta Therapeutics compared to the current price of 108.5 €.
So far the community has only identified positive things for Sarepta Therapeutics stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Sarepta Therapeutics in the next few years
Pros
?
M***** P*******
?
G***** c******* t* c**********
?
C******** o* t** e**********
Cons
?
S********** s********
?
W********* I********* f** t** n*** y****
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Sarepta Therapeutics vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Sarepta Therapeutics | -0.910% | -5.685% | -3.947% | -4.325% | 23.757% | 82.683% | 4.885% |
| Exact Sciences | 1.130% | -12.960% | 10.118% | 0.000% | -12.972% | -45.058% | -29.420% |
| Incyte Corp. | -0.300% | -3.086% | -6.023% | -26.249% | -12.548% | -28.066% | -24.186% |
| Regeneron Pharmaceuticals Inc. | 1.410% | -2.076% | -4.969% | 13.999% | 5.279% | 100.119% | 181.367% |
Comments
News
Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling?
Sarepta Therapeutics (NASDAQ: SRPT) could have a serious new competitor on the horizon. According to some fresh clinical data from Regenxbio (NASDAQ: RGNX), another biotech, the company is making
Sarepta Therapeutics Stock Has 73% Upside, According to 1 Wall Street Analyst
On Feb. 20, Wedbush financial analyst Andreas Argyrides restated his price target for Sarepta Therapeutics (NASDAQ: SRPT) stock, claiming that its shares would reach $224, rising 73% in the process
Sarepta Therapeutics (SRPT) Q4 2023 Earnings Call Transcript
Image source: The Motley Fool.
Sarepta Therapeutics (NASDAQ: SRPT)Q4 2023 Earnings CallFeb 28, 2024, 4:30 p.m. ET
Operator
Source Fool.com